Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04121780 · ClinicalTrials.gov registry record · Phase 2

Growth Hormone Replacement Therapy for Retried Professional Football Players

A Phase 2 study of TBI (Traumatic Brain Injury) and Concussion, Brain, sponsored by Center for Neurological Studies.

Recruiting
Registry status
Phase 2
Development phase
42
Enrollment target
1
Study location

NCT04121780 is a Phase 2 study of TBI (Traumatic Brain Injury) and Concussion, Brain that is actively recruiting participants, run by Center for Neurological Studies. The registered enrollment target is 42 participants, below the 171-participant average among 20 other TBI (Traumatic Brain Injury) trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04121780, a Phase 2 study of TBI (Traumatic Brain Injury) and Concussion, Brain, is actively recruiting participants, sponsored by Center for Neurological Studies.

RECRUITING
Registry status
Phase 2
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).

Interventions

  • OTHER Placebo
  • BIOLOGICAL Growth Hormone

Study Locations (1)

Michigan

  • Center for Neurolgoical Studies (CNS) - Dearborn

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2019-10-08
Est. Completion 2026-09
Phase Phase 2

Sponsor

Center for Neurological Studies

1 total trials

What the Registry Record Tells You About NCT04121780

The ClinicalTrials.gov registry entry for NCT04121780 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 20 other TBI (Traumatic Brain Injury) trials with a reported enrollment target (75% lower). The listed sponsor is Center for Neurological Studies, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with TBI (Traumatic Brain Injury) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04121780 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT04121780 about?

NCT04121780 is a clinical study titled "Growth Hormone Replacement Therapy for Retried Professional Football Players". This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).

What is the current status of trial NCT04121780?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2019-10-08. Estimated completion is 2026-09.

What conditions does trial NCT04121780 study?

This clinical trial studies the following conditions: TBI (Traumatic Brain Injury), Concussion, Brain, Growth Hormone Deficiency, Hypopituitarism, Sport Injury.

What interventions are being tested in trial NCT04121780?

The interventions under investigation include: Placebo (OTHER), Growth Hormone (BIOLOGICAL).

Who is sponsoring clinical trial NCT04121780?

This trial is sponsored by Center for Neurological Studies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04121780 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for TBI (Traumatic Brain Injury)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.